Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 2;2016(1):552-560.
doi: 10.1182/asheducation-2016.1.552.

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions

Jamile M Shammo  1 , Brady L Stein  2
Affiliations
Review

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions

Jamile M Shammo et al. Hematology Am Soc Hematol Educ Program. .

Abstract

The last decade has witnessed tremendous scientific advances, ushered in by the JAK2 V617F discovery, contributing to enhanced diagnostic capability and understanding of the biology of myeloproliferative neoplasms (MPNs). Discovery of the calreticulin mutations filled a diagnostic gap; more recent work sheds light on its contribution to disease pathogenesis, and prognosis. Recent studies have also identified novel JAK2 and MPL mutations in patients with essential thrombocythemia and myelofibrosis (MF). Especially in MF, the driver mutational profile has prognostic implications, with additive contributions from the acquisition of additional somatic mutations. The hope is that sophisticated molecular profiling will not only aid in prognostication, but also guide selection of therapy for patients with MPNs.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.M.S. has received research funding, consulted for, received honorarium from, and has been affiliated with the Speakers Bureau for Alexion, Incyte, Novartis, and Celgene. B.L.S. has consulted for Incyte.

Figures

Figure 1.
Figure 1.
(A) How we approach the management of ET and PV. (B) How we approach nontransplant management of MF. CV, cardiovascular; Epo, erythropoietin; ESA, erythropoiesis-stimulating agent; Hct, hematocrit; HU, hydroxyurea; PBT, phlebotomy; Plts, platelets; symptoms (bone pain, fever, night sweats, and weight loss).
Figure 2.
Figure 2.
(A) Evolution in prognostic assessment: ET. Constructed prior to CALR discovery (*). CALR co-segregates with younger age and absent thrombosis risk, and therefore, does not modify IPSET score (**). Unable to predict MF or AML risk (***). (B) Evolution in prognostic assessment: PV. (C) Evolution in prognostic assessment: MF. The latest proposed MF scoring systems incorporate molecular and genetic information in the assessment (*). The GPSS identified very high (3 points) and high-risk karyotypes (2 points), TN status (2 points), JAK2/MPL-mutated (2 points), type-2/type-2–like CALR-mutated (2 points), ASXL1-mutated (1 point), and SRSF2-mutated (1 point), as independent predictors of shortened survival; these variables were included in this score, along with age >60 years. Another system, the Mutation-enhanced IPSS (MIPSS), analyzed 986 PMF patients, identifying age >60, constitutional symptoms, Hb <10 g/dL, platelets <200 × 109/L, TN status (1.5 points), JAK2-mutated or MPL-mutated (0.5 points), ASXL1-mutated (0.5 points), and SRSF2-mutated (0.5 points) status as significant, adverse indicators. CV, cardiovascular; DIPSS, dynamic IPSS; GPSS, genetics-based Prognostic Scoring System; pts, patients.
See this image and copyright information in PMC

References

    1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-375. - PubMed
    1. Baxter EJ, Scott LM, Campbell PJ, et al. ; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. - PubMed
    1. James C, Ugo V, Le Couédic JP, et al. . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. - PubMed
    1. Kralovics R, Passamonti F, Buser AS, et al. . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. - PubMed
    1. Levine RL, Wadleigh M, Cools J, et al. . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. - PubMed

MeSH terms